|
Bieżący numer
Archiwum
O czasopiśmie
Rada naukowa
Recenzenci
Bazy indeksacyjne
Kontakt
Zasady publikacji prac
Opłaty publikacyjne
Standardy etyczne i procedury
Panel Redakcyjny
Zgłaszanie i recenzowanie prac online
|
2/2022
vol. 7 Artykuł oryginalny
Ocena poziomu wiedzy i postaw pacjentów onkologicznych w zakresie dostępu naczyniowego typu port dożylny
Renata Piotrkowska
1
,
Piotr Jarzynkowski
1
,
Marcelina Bożejewicz
1
,
Katarzyna Kwiecień-Jaguś
2
Data publikacji online: 2022/08/28
Plik artykułu:
- 2.pdf
[0.12 MB]
ENW EndNote
BIB JabRef, Mendeley
RIS Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
1. Morris WJ, Tyldesley S, Rodda S et al. Androgen suppression combined with elective nodal and dose escalated radiation therapy (the ASCENDE-RT Trial): an analysis of survival endpoints for a randomized trial comparing low-dose-rate brachytherapy boost to dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 2017; 98: 275-285. 2.
Tharmalingam H, Tsang Y, Choudhury A et al. External beam radiation therapy (EBRT) and high-dose-rate (HDR) brachytherapy for intermediate and high-risk prostate cancer: the impact of EBRT volume. Int J Radiat Oncol Biol Phys 2020; 106: 525-533. 3.
Dutta SW, Alonso CE, Libby B, Showalter TN. Prostate cancer high dose-rate brachytherapy: review of evidence and current perspectives. Expert Rev Med Devices 2018; 15: 71-79. 4.
Hoskin PJ, Motohashi K, Bownes P et al. High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: initial results of a randomised phase three trial. Radiother Oncol 2007; 84: 114-120. 5.
Hoskin PJ, Rojas AM, Bownes PJ et al. Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Radiother Oncol 2012; 103: 217-222. 6.
Crook J, Marbán M, Batchelar D. HDR prostate brachytherapy. Semin Radiat Oncol 2020; 30: 49-60. 7.
Andreoiu M, Cheng L. Multifocal prostate cancer: biologic, prognostic, and therapeutic implications. Hum Pathol 2010; 41: 781-793. 8.
Tolkach Y, Kristiansen G. The heterogeneity of prostate cancer: a practical approach. Pathobiology 2018; 85: 108-116. 9.
Hentschel B, Oehler W, Strauß D et al. Definition of the CTV prostate in CT and MRI by using CT-MRI image fusion in IMRT planning for prostate cancer. Strahlenther Onkol 2011; 187: 183-190. 10.
Rasch C, Barillot I, Remeijer P et al. Definition of the prostate in CT and MRI: a multi-observer study. Int J Radiat Oncol Biol Phys 1999; 43: 57-66. 11.
Salembier C, Villeirs G, De Bari B et al. ESTRO ACROP consensus guideline on CT- and MRI-based target volume delineation for primary radiation therapy of localized prostate cancer. Radiother Oncol 2018; 127: 49-61. 12.
Sanda MG, Cadeddu JA, Kirkby E et al. Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. Part I: risk stratification, shared decision making, and care options. J Urol 2018; 199: 683-690. 13.
Sanda MG, Cadeddu JA, Kirkby E et al. Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. Part II: recommended approaches and details of specific care options. J Urol 2018; 199: 990-997. 14.
Cellini N, Morganti AG, Mattiucci GC et al. Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: implications for conformal therapy planning. Int J Radiat Oncol Biol Phys 2002; 53: 595-599. 15.
Arrayeh E, Westphalen AC, Kurhanewicz J et al. Does local recurrence of prostate cancer after radiation therapy occur at the site of primary tumor? Results of a longitudinal MRI and MRSI study. Int J Radiat Oncol Biol Phys 2012; 82: e787-e793. 16.
McNeal JE, Price HM, Redwine EA et al. Stage A versus stage B adenocarcinoma of the prostate: morphological comparison and biological significance. J Urol 1988; 139: 61-65. 17.
Kerkmeijer LGW, Groen VH, Pos FJ et al. Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase III trial. J Clin Oncol 2021; 39: 787-796. 18.
von Eyben FE, Kiljunen T, Kangasmaki A et al. Radiotherapy boost for the dominant intraprostatic cancer lesion – a systematic review and meta-analysis. Clin Genitourin Cancer 2016; 14: 189-197. 19.
Pieters B, Wijkstra H, van Herk M et al. Contrast-enhanced ultrasound as support for prostate brachytherapy treatment planning. J Contemp Brachytherapy 2012; 4: 69-74. 20.
Tissaverasinghe S, Crook J, Bachand F et al. Dose to the dominant intraprostatic lesion using HDR vs. LDR monotherapy: a phase II randomized trial. Brachytherapy 2019; 18: 299-305. 21.
Fischbach F, Hass P, Schindele D et al. MRI targeted single fraction HDR brachytherapy for localized prostate carcinoma: a feasibility study of focal radiation therapy (ProFocAL). Eur Radiol 2020; 30: 2072-2081. 22.
Wang T, Press RH, Giles M et al. Multiparametric MRI-guided dose boost to dominant intraprostatic lesions in CT-based High-dose-rate prostate brachytherapy. Br J Radiol 2019; 92: 20190089. 23.
Gomez-Iturriaga A, Casquero F, Urresola A et al. Dose escalation to dominant intraprostatic lesions with MRI-transrectal ultrasound fusion high-dose-rate prostate brachytherapy. Prospective phase II trial. Radiother Oncol 2016; 119: 91-96. 24.
Lakosi F, Antal G, Pall J et al. HDR brachytherapy boost using MR-only workflow for intermediate- and high-risk prostate cancer: 8-year results of a pilot study. Brachytherapy 2021; 20: 576-583. 25.
Mason J, Al-Qaisieh B, Bownes P et al. Multi-parametric MRI-guided focal tumor boost using HDR prostate brachytherapy: a feasibility study. Brachytherapy 2014; 13: 137-145. 26.
Rodda S, Tyldesley S, Morris WJ et al. ASCENDE-RT: an analysis of treatment-related morbidity for a randomized trial comparing a low-dose-rate brachytherapy boost with a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 2017; 98: 286-295. 27.
Camarata AS, Nickleach DC, Jani AB, Rossi PJ. Locoregional prostate cancer treatment pattern variation in independent cancer centers: policy effect, patient preference, or physician incentive? Health Serv Insights 2015; 8: 1-8. 28.
Orio PF, III, Nguyen PL, Buzurovic I et al. Prostate brachytherapy case volumes by academic and nonacademic practices: implications for future residency training. Int J Radiat Oncol Biol Phys 2016; 96: 624-628. 29.
Beuthien-Baumann B, Koerber SA. PET imaging in adaptive radiotherapy of prostate tumors. Q J Nucl Med Mol Imaging 2018; 62: 404-410. 30.
Gaudreault M, Chang D, Hardcastle N et al. Feasibility of biology-guided radiotherapy using PSMA-PET to boost to dominant intraprostatic tumour. Clin Transl Radiat Oncol 2022; 35: 84-89. 31.
Goodman CD, Fakir H, Pautler S et al. Dosimetric evaluation of PSMA PET-delineated dominant intraprostatic lesion simultaneous infield boosts. Adv Radiat Oncol 2020; 5: 212-220.
|
ENGLISH
